De Novo device
Lumipulse G ß-Amyloid Ratio (1-42/1-40)
Fujirebio Diagnostics,Inc. · AlzheimerS Disease Pathology Assessment Test (QSE, Class II) · First FDA decision May 4, 2022, newest May 4, 2022Alzheimer's disease and dementia
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
0
Naming "Lumipulse G Amyloid"
MAUDE reports
0
Brand "Lumipulse G Amyloid", since 2015
PubMed studies
0
Mentioning "Lumipulse G Amyloid"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Lumipulse G ß-Amyloid Ratio (1-42/1-40)New device typeBreakthroughDe Novo
DEN200072 · Decided May 4, 2022 · 530 days after receipt
Device type: AlzheimerS Disease Pathology Assessment Test (QSE) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Lumipulse G Amyloid", any status and sponsor, newest update first.
No registered device study names "Lumipulse G Amyloid".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Lumipulse G Amyloid", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QSE
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Lumipulse G Amyloid"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code QSE.
- Elecsys ß-Amyloid (1-42) CSF II, Elecsys Total-Tau CSFRoche Diagnostics · 510(k) 2023
- Elecsys B-Amyloid (1-42) CSF II, Elecsys Phospho-Tau (181P) CSFRoche Diagnostics · 510(k) 2022
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.